[Buccal manifestations in patients submitted to chemotherapy].
Several changes in the oral cavity due to chemotherapy can be observed and can lead to important systemic complications, increasing the time of the patient in hospital and the costs of the treatment as well as affect the quality of life of the patients. The aim of this study was to assess the oral manifestation in patients treated with chemotherapy according to sex, age and tumor type. Data was collected in an oncology hospital in Juiz de Fora, Minas Gerais State, from patients' records that were submitted to oncologic treatment. It was possible to verify that mucositis, associated or not to other type of lesions, was the most common lesion in both sex of all ages (15.5%). Xerostomia and other lesions, such as Candida infection and aphthous lesions, were also present. It is possible to improve the quality of life of the patient during and after anti-neoplastic therapies through a protocol of odontological assistance that includes changes of the oral environment previous to chemotherapy such as profilaxis, caries removal, treatment of periodontal and periapical lesions, oral hygiene instructions, diet orientation and laser therapy. It is very important the insertion of the dentist in the oncologic medical team for the early diagnosis of the oral manifestation and follow-up during treatment time.
Hespanhol
Fernando Luiz
FL
Faculdade de Odontologia, Suprema - Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Salvaterra, Juiz de Fora MG, Brazil. hespanhol@croe.com.br
Tinoco
Eduardo Muniz Barretto
EM
Teixeira
Henrique Guilherme de Castro
HG
Falabella
Márcio Eduardo Vieira
ME
Assis
Neuza Maria de Souza Picorelli
NM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced* / Q000453:epidemiology; D055815:Young Adult
D000970:Antineoplastic Agents